In combination with disease-modifying antirheumatic drugs (DMARDs), tocilizumab improved signs and symptoms of RA [1-3] and inhibited radiographic progression of RA [4] in patients with inadequate responses to DMARDs or TNF inhibitors. The gene discussed is TNF; the disease is rheumatoid arthritis.